Below is a resource for our patients:

Taylor & Francis is a publisher of peer-reviewed medical journals. We publish a type of article called Plain Language Summary of Publications (PLSPs)....

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.
A three-way tussle has...

Be sure to catch up on the latest happenings in our fall newsletter here!

– ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients...

03.31.2025 at 10:00 AM EDT

• Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved...